133 related articles for article (PubMed ID: 9309334)
1. Expression of pS2, c-erbB-2, and cathepsin D during the menstrual cycle in human breast cancers.
Khan SA; Gonchoroff NJ; Miller LE
Ann Surg Oncol; 1997 Sep; 4(6):462-9. PubMed ID: 9309334
[TBL] [Abstract][Full Text] [Related]
2. Time at surgery during menstrual cycle and menopause affects pS2 but not cathepsin D levels in breast cancer.
Pujol P; Daurès JP; Brouillet JP; Maudelonde T; Rochefort H; Grenier J
Br J Cancer; 1999 Feb; 79(5-6):909-14. PubMed ID: 10070889
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
[TBL] [Abstract][Full Text] [Related]
5. Expression of cathepsin D and pS2 in imprint smears of breast carcinoma.
Athanassiadou PP; Athanassiades PH; Davaris P; Petrakakou EI; Zerva CI; Kyrkou KA
Cytopathology; 1998 Aug; 9(4):240-7. PubMed ID: 9710694
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer.
Fulco RA; Petix M; Salimbeni V; Torre EA
Minerva Med; 1998; 89(1-2):5-10. PubMed ID: 9561019
[TBL] [Abstract][Full Text] [Related]
7. Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle.
Balsari A; Casalini P; Tagliabue E; Greco M; Pilotti S; Agresti R; Giovanazzi R; Alasio L; Rumio C; Cascinelli N; Colnaghi MI; Ménard S
Am J Pathol; 1999 Nov; 155(5):1543-7. PubMed ID: 10550311
[TBL] [Abstract][Full Text] [Related]
8. A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.
Pujol P; Daures JP; Brouillet JP; Chang S; Rouanet P; Bringer J; Grenier J; Maudelonde T
Cancer; 2001 May; 91(10):1854-61. PubMed ID: 11346866
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-regulated cut-off values of pS2 and cathepsin D expression in breast carcinomas.
Markićević M; Petrović A; Kanjer K; Nesković-Konstantinović Z; Nikolić-Vukosavujević D
Adv Exp Med Biol; 2008; 617():341-8. PubMed ID: 18497057
[TBL] [Abstract][Full Text] [Related]
10. [Cytosolic pS2 levels in 154 non-small-cell lung carcinomas. Correlation with other clinical and biological parameters].
Ruibal A; Núñez MI; del Río MC; García Díez S; Rodríguez J; Alvarez De Linera JA
Rev Esp Med Nucl; 2002 Apr; 21(2):109-14. PubMed ID: 11879619
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle.
Gompel A; Martin A; Simon P; Schoevaert D; Plu-Bureau G; Hugol D; Audouin J; Leygue E; Truc JB; Poitout P
Breast Cancer Res Treat; 1996; 38(2):227-35. PubMed ID: 8861841
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
13. Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: inconsistency with their established prognostic significance.
Ardavanis A; Gerakini F; Amanatidou A; Scorilas A; Pateras C; Garoufali A; Pissakas G; Stravolemos K; Apostolikas N; Yiotis I
Anticancer Res; 1997; 17(5A):3665-9. PubMed ID: 9413220
[TBL] [Abstract][Full Text] [Related]
14. Differential distribution of ErbB-2 and pS2 proteins in ductal carcinoma in situ of the breast.
Inaji H; Koyama H; Motomura K; Noguchi S
Breast Cancer Res Treat; 1996; 37(1):89-92. PubMed ID: 8750531
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cathepsin-D and pS2 protein levels in human breast cancer cell lines.
Cappelletti V; Fioravanti L; Miodini P; Di Fronzo G
Tumour Biol; 1996; 17(5):290-8. PubMed ID: 8792855
[TBL] [Abstract][Full Text] [Related]
16. Receiver-operating characteristic (ROC) curve analysis of cathepsin D and pS2 in breast disease; results from a prospective study.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM
Anticancer Res; 1999; 19(4C):3463-7. PubMed ID: 10629636
[TBL] [Abstract][Full Text] [Related]
17. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.
Chalbos D; Philips A; Galtier F; Rochefort H
Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199
[TBL] [Abstract][Full Text] [Related]
18. Status of estrogen and progesterone receptors in various phases of the menstrual cycle in breast cancer.
Vasei M; Azarpira N; Talei A
Arch Iran Med; 2006 Jul; 9(3):250-3. PubMed ID: 16859061
[TBL] [Abstract][Full Text] [Related]
19. Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor.
Cooper LS; Gillett CE; Patel NK; Barnes DM; Fentiman IS
Cancer; 1999 Nov; 86(10):2053-8. PubMed ID: 10570431
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
